| abstract |
The present invention relates to a sustained release pharmaceutical composition comprising mosaprid or a salt thereof, wherein the composition of the present invention initially meets the effective blood concentration of mosapride by satisfying a unique two-phase dissolution profile (immediate release phase and delayed release phase). It can be reached quickly, and in the late period, the effective blood concentration can be continuously maintained to increase the efficacy of mosapride by taking a single dosage form once a day, as well as to improve medication compliance. |